Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelimab plus liposomal irinotecan-based chemotherapy for first-line treatment of pancreatic cancer with liver metastases
ChiCTR2400087095Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in pancreatic cancer with hepatic metastases, sponsored by Shanghai General Hospital. Primary endpoint: Objective response rate (ORR). Planned start Jul 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic cancer with hepatic metastases
Beyond the preview
Go deeper on ChiCTR2400087095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087095.